Are statins applicable for the prevention and treatment of zygomycosis?

Clinical Infectious Diseases

Volumn 49, Issue 3, 2009, Pages 483-484

  Galgóczy, László ^a   Nyilasi, Ildikó ^b   Papp, Tamiĺs ^a   Vágvölgyi, Csaba ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b PannonPharma ^*  (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ATORVASTATIN; CASPOFUNGIN; CERIVASTATIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; FLUCONAZOLE; FLUCYTOSINE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MICONAZOLE; PITAVASTATIN; POSACONAZOLE; PRAVASTATIN; RAVUCONAZOLE; ROSUVASTATIN; SIMVASTATIN; SURAMIN; TERBINAFINE; UNINDEXED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; COMBINATION CHEMOTHERAPY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG POTENTIATION; FUNGUS GROWTH; HUMAN; IN VITRO STUDY; LETTER; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MUCORMYCOSIS; NONHUMAN; PRIORITY JOURNAL; SERUM; ZYGOMYCETES;

ANTICHOLESTEREMIC AGENTS; ANTIFUNGAL AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; SERUM; ZYGOMYCOSIS;

EID: 67651113649     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/600825     Document Type: Letter

References (11)

1. Sun HY, Singh N. Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients. Clin Infect Dis 2009; 48:745-55.
2. Lukács G, Papp T, Nyilasi I, Nagy E, Vágvölgyi C. Differentiation of Rhizomucor species on the basis of their different sensitivities to lo- vastatin. J Clin Microbiol 2004;42:5400-2.
3. Chamilos G, Lewis RE, Kontoyiannis DP. Lo- vastatin has significant activity against Zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother 2006; 50:96-103.
4. Galgóczy L, Papp T, Lukács G, et al. Interactions between statins and Penicillium chry- sogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes. FEMS Microbiol Lett 2007;270:109-15.
5. Galgóczy L, Papp T, Vágvölgyi, C. In vitro interaction between suramin and fluvastat- in against clinically important Zygomycetes. Mycoses doi: 10.1111/j.1439-0507.2008.01634.x. Published 18 October 2008.
6. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and phar- macokinetic properties of statins. Pharmacol Ther 1999;84:413-28.
7. Kajinami K, Takekoshi N, Saito Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2003;21:199-215.
8. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties ofstatins: an update. Fundam Clin Pharmacol 2005; 19:117-25.
9. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109(23 Suppl 1):III50-7.
10. Corsini A, Bellosta A, Davidson HM. Phar- macokinetic interactions between statins and fibrates. Am J Cardiol 2005;96:44-9.
11. Buemi M, Floccari F, Nostro L, et al. Statins in the prevention of cardiovascular events in patients with renal failure. Cardiovasc He- matol Disord Drug Targets 2007; 7:7-13.